PPT-Evidence-Based Antiplatelet Therapy Across the ACS Spectrum

EvidenceBased Antiplatelet Therapy Across the ACS Spectrum Panelists Program Goals Case Study Case Study cont Presenting ECG Guideline for UrgentImmediate Invasive Strategy 1A Recommendation An Immediate Invasive Strategy. Therapy for Secondary Prevention . Beyond One Year . Following . ACS or PCI. Working Group. : . Anil Gupta MD, FRCPC, Pierre Theroux MD, FRCPC . Canadian Cardiovascular Society Antiplatelet Guidelines. Tx. : . Real-World Practice. In the US, ~800,000 AF patients are on concomitant OAC and antiplatelet tx. 1. Patients on chronic OAC with CAD are 7x more likely to receive concomitant antiplatelet tx. Therapy for the Secondary Prevention of . Cerebrovascular. Disease. Working Group: . Ashfaq. . Shuaib. , MD, . FRCP; Philip . Teal, MD, FRCP. Canadian Cardiovascular Society . Antiplatelet Guidelines. Antiplatelet Guidelines. HEART FAILURE. Working Group: . Alan D. Bell, MD, CCFP; James D. . Douketis. , MD, FRCP. Objectives. Interpret . the . Canadian Cardiovascular Society Guideline . recommendations . Working Group: . Maria E. Wolfs, MD, FRCP; . Rémi. . Rabasa-Lhoret. , MD, PhD. Canadian Cardiovascular Society Antiplatelet . Guidelines. Objectives. Interpret . the . Canadian Cardiovascular Society Guideline recommendations regarding the use of antiplatelet . GRACE. . 5-Year Mortality . Antiplatelet Therapy. Cornerstone of Medical Therapy Post ACS. TRA 2P-TIMI 50. Efficacy/Safety. ATLAS ACS 2—TIMI 51. Study Design. ATLAS-2. . Baseline Patient Characteristics. Presentation by . R. on . J. ohanson OAM ACS. Peter James ACS, ASC & Calvin Gardiner ACS. THE FUTURE OF THE . . CINEMATOGRAPHER. We . live in the most exciting time for cinematography with the development of Digital cameras and lenses capable of extraordinary quality and incredible devices to move the camera in ways previously only dreamt . Presentation by . R. on . J. ohanson OAM ACS. Peter James ACS, ASC & Calvin Gardiner ACS. THE FUTURE OF THE . . CINEMATOGRAPHER. We . live in the most exciting time for cinematography with the development of Digital cameras and lenses capable of extraordinary quality and incredible devices to move the camera in ways previously only dreamt . Minilecture. Objectives. Indications for Antiplatelet Therapy in patients with CAD and ACS. Antiplatelet Therapy in the role of primary and secondary prevention of . c. ardiovascular events. CAD & the Vulnerable Plaque. Minilecture. Objectives. Indications for Antiplatelet Therapy in patients with CAD and ACS. Antiplatelet Therapy in the role of primary and secondary prevention of . c. ardiovascular events. CAD & the Vulnerable Plaque. Akhtar . Fajar. . Muzakkir. New ESC NSTEMI Guideline. Collet JP et al European Heart Journal (2020) 00, 1-79 . What is NEW?. Collet JP et al European Heart Journal (2020) 00, 1-79 . Major Changes in Recommendation. Anticoagulant therapy. (n = . 124). CADISS. P. rimary outcome. : . Ipsilateral . stroke or all-cause mortality . for antiplatelet vs. anticoagulation: 2. % . vs. 1%; p . = . 0.63. Any stroke: 2% vs. 1%, . 12. inhibitor to dual pathway inhibition with aspirin plus vascular-dose rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study. Luis Ortega-Paz, MD, PhD. 1. ; Francesco Franchi, MD. Robert D. Acton, MD, FACS. History of Project. Description of Modules. Description of Assessments. Demonstration of Modules. Venipuncture . Communication – Hand -off. Summary. Outline. History. ASE 2009 – Lunch Symposium.